A Randomized, Phase II Trial Of Intermittent Versus Continuous Dosing Of Dabrafenib (Nsc-763760) And Trametinib (Nsc-763093) In Brafv600e/K Mutant Mel
Posted Date: May 15, 2019
- Investigator: John Morris
- Type of Study: Drug
The purpose of this study is to compare good and bad effects of receiving the drugs dabrafenib and trametinib continuously to receiving dabrafenib and trametinib with a break in treatment. The combination has been approved by the FDA for the treatment of advanced melanoma. This study will allow rese
Criteria:
To Be Eligible For This Study, Patients Must Have Melanoma With The Braf Mutation.
Keywords:
Melanoma, Mutant , Cancer, Skin Cancer, S1320
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu